Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Latest News

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results

Read More

Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Read More

Ligand to Report Fourth Quarter Financial Results on February 22

Read More

Recent Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range